机构:[1]Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[4]Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China.四川大学华西医院[5]Lung Cancer Treatment Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[6]Chengdu OrganoidMed Medical Laboratory, West China Health Valley, Chengdu, China.[7]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Guangzhou, China.[8]Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.[9]Howard Hughes Medical Institute, Chevy Chase, MD, USA
This work was supported by the National Key R&D Program of China (2017YFA0505600,
C.C.), the National Natural Science Foundation of China (81522003, 82170171, 81770157
and 81570150, C.C.; 81570150, F.N.; 8210102196, J.C.), the Sichuan Science and
Technology Program (2020YFQ0059, 2020ZYD002, 2018JZ0077 and 2017TJPT0005,
C.C.) and the 1.3.5. Project for Disciplines of Excellence, West China Hospital,
Sichuan University (C.C.).
第一作者机构:[1]Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.[2]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714):
Na Feifei,Pan Xiangyu,Chen Jingyao,et al.KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.[J].NATURE CANCER.2022,3(6):753-+.doi:10.1038/s43018-022-00361-6.
APA:
Na Feifei,Pan Xiangyu,Chen Jingyao,Chen Xuelan,Wang Manli...&Chen Chong.(2022).KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming..NATURE CANCER,3,(6)
MLA:
Na Feifei,et al."KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming.".NATURE CANCER 3..6(2022):753-+